Fujifilm Corporation’s Life Sciences teams, a portfolio of businesses offering products, services and integrated solutions that cover all stages of therapeutic development from Discovery to commercialization, have announced new names and identities today as part of a strategic effort effort. The new names of the team companies, the cooperative strategic focus and structural alignment reflect Fujifilm’s commitment to life sciences, offering fully integrated end to end to the entire life cycle of drug development-from research and discovery.
Fujifilm Irvine Scientific, based in Santa Ana, California is stirred as Fujifilm Biosciences as part of this new structure and strategy. The new name includes the evolution of Fujifilm Biosciences over the last 55 years – from its formation in 1970 to its recent extension to serve wider communities and clients of the Life Sciences. It is also a nod to its scientific roots as a pioneer in the media industry with a basic focus on innovation and quality. Today, Fujifilm Biosciences offers a comprehensive portfolio of discovery and research reagents, recombinant growth factors and proteins, specific chemicals and critical materials, in addition to the strong means of cell cultivation and solutions in the US, January 1, 2026.
Fujifilm Diosynth Biotechnologies, a leading World Development and Construction Organization (CDMO), acquired for the first time by the Fujifilm group in 2011, is rejected in Biotechnologies Fujifilm. The company serves its global partners that offer opportunities for processing processes through commercial supply, world -class productive activities across Europe and the US the legal name of the company will not change.
In the last 15 years, Fujifilm has invested more than $ 10 billion through extensions and acquisitions to build the capabilities of end to end life to create a accelerated path to more patients for advanced care.
“Under the umbrella” Life Partners “, the companies of our lives offer complete solutions to pharmaceutical and biotechnological markets, aligning both with our strategic growth programs and our commitment to innovation.” Commented by Toshihisa Iida, Director, Corporate Vice President, General Manager of the Life Strategy Strategy Headquarters and Bio CDMO address, Fujifilm Corporation, Japan. “With the redefinition of our biological science team, we also support Fujifilm’s development strategy for the Life Sciences field, where we believe that unification with a single banner will simplify the commitment to our global customer network throughout Healthcare, we are creating new pharmaceutical companies value and support of pharmaceutical companies, biotechnology and academic community companies in both drug support solutions and CDMO services. “
“Fujifilm Biosciences focuses on supporting our partners in the ambitions of their lives and do everything we can to be able to achieve their success along the way.” This Brandon Pence, President and CEO, Fujifilm Biosciences. “Our foundation is based on the basic principles of the placement of our people, transforming innovation and science and maintaining the commitment to unprecedented customer service.
At Fujifilm Biotechnologies, we have huge pride in the value we bring to our partners daily to help bring life -changing medicines to patients. “
This closer coordination and United Focus enhance the way we interact and deliver for our customers. Together, we offer deep knowledge and experience, speed, flexibility and scientific rigor – critical elements to bring complex biologists to life. ”
Lars Petersen, President and CEO, Fujifilm Biotechnologies
Along with Biosciences Fujifilm and Fujifilm biotechnologies, Fujifilm Life Sciences Group also include Fujifilm Cellular Dynamics, a leading manufacturer and manufacturer Corporation and Fujifilm Toyama Co., Ltd.
